» Articles » PMID: 18793339

The Molecular Analysis of Trypanosoma Cruzi Metallocarboxypeptidase 1 Provides Insight into Fold and Substrate Specificity

Overview
Journal Mol Microbiol
Date 2008 Sep 17
PMID 18793339
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Trypanosoma cruzi is the aetiological agent of Chagas' disease, a chronic infection that affects millions in Central and South America. Proteolytic enzymes are involved in the development and progression of this disease and two metallocarboxypeptidases, isolated from T. cruzi CL Brener clone, have recently been characterized: TcMCP-1 and TcMCP-2. Although both are cytosolic and closely related in sequence, they display different temporary expression patterns and substrate preferences. TcMCP-1 removes basic C-terminal residues, whereas TcMCP-2 prefers hydrophobic/aromatic residues. Here we report the three-dimensional structure of TcMCP-1. It resembles an elongated cowry, with a long, deep, narrow active-site cleft mimicking the aperture. It has an N-terminal dimerization subdomain, involved in a homodimeric catalytically active quaternary structure arrangement, and a proteolytic subdomain partitioned by the cleft into an upper and a lower moiety. The cleft accommodates a catalytic metal ion, most likely a cobalt, which is co-ordinated by residues included in a characteristic zinc-binding sequence, HEXXH and a downstream glutamate. The structure of TcMCP-1 shows strong topological similarity with archaeal, bacterial and mammalian metallopeptidases including angiotensin-converting enzyme, neurolysin and thimet oligopeptidase. A crucial residue for shaping the S(1') pocket in TcMCP-1, Met-304, was mutated to the respective residue in TcMCP-2, an arginine, leading to a TcMCP-1 variant with TcMCP-2 specificity. The present studies pave the way for a better understanding of a potential target in Chagas' disease at the molecular level and provide a template for the design of novel therapeutic approaches.

Citing Articles

From Data Mining of sp. Genome to Enzyme Discovery of a Hyperthermophilic Metallocarboxypeptidase.

Fernandes G, Sierra E, Brear P, Rangel Pereira M, Lemos E Microorganisms. 2021; 9(2).

PMID: 33673011 PMC: 7918520. DOI: 10.3390/microorganisms9020393.


Potent and selective inhibitors for M32 metallocarboxypeptidases identified from high-throughput screening of anti-kinetoplastid chemical boxes.

Salas-Sarduy E, Uran Landaburu L, Carmona A, Cazzulo J, Aguero F, Alvarez V PLoS Negl Trop Dis. 2019; 13(7):e0007560.

PMID: 31329594 PMC: 6675120. DOI: 10.1371/journal.pntd.0007560.


The Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases-Part III: In-Silico Molecular Docking Investigations.

Ogungbe I, Setzer W Molecules. 2016; 21(10).

PMID: 27775577 PMC: 6274513. DOI: 10.3390/molecules21101389.


Synthetic Medicinal Chemistry in Chagas' Disease: Compounds at The Final Stage of "Hit-To-Lead" Phase.

Cerecetto H, Gonzalez M Pharmaceuticals (Basel). 2016; 3(4):810-838.

PMID: 27713281 PMC: 4034012. DOI: 10.3390/ph3040810.


A global comparison of the human and T. brucei degradomes gives insights about possible parasite drug targets.

Mashiyama S, Koupparis K, Caffrey C, McKerrow J, Babbitt P PLoS Negl Trop Dis. 2012; 6(12):e1942.

PMID: 23236535 PMC: 3516576. DOI: 10.1371/journal.pntd.0001942.